These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

781 related items for PubMed ID: 32342201

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type EGFR Family Members.
    Yan D, Parker RE, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK.
    Clin Cancer Res; 2018 Dec 15; 24(24):6523-6535. PubMed ID: 30194074
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.
    Kim B, Park YS, Sung JS, Lee JW, Lee SB, Kim YH.
    Cancer Med; 2021 Jan 15; 10(1):372-385. PubMed ID: 33314735
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P, Xiang Y, Liu X, Zhang T, Yang R, Chen S, Xu L, Yu Q, Zhao H, Zhang L, Liu Y, Si Y.
    Molecules; 2019 Feb 12; 24(3):. PubMed ID: 30759826
    [Abstract] [Full Text] [Related]

  • 9. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K, Okamoto I, Tanizaki J, Kuwata K, Yamaguchi H, Fukuoka M, Nishio K, Nakagawa K.
    Mol Cancer Ther; 2010 Jun 12; 9(6):1647-56. PubMed ID: 20530710
    [Abstract] [Full Text] [Related]

  • 10. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
    Wang L, Liu J, Liu J, Chen X, Chang M, Li J, Zhou J, Bai C, Song Y.
    J Cancer Res Clin Oncol; 2019 Apr 12; 145(4):861-872. PubMed ID: 30661098
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
    Shen L, Li Z, Shen S, Niu X, Yu Y, Li Z, Liao M, Chen Z, Lu S.
    Lung Cancer; 2012 Dec 12; 78(3):193-200. PubMed ID: 22985911
    [Abstract] [Full Text] [Related]

  • 14. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
    Chen P, Huang HP, Wang Y, Jin J, Long WG, Chen K, Zhao XH, Chen CG, Li J.
    J Exp Clin Cancer Res; 2019 Jun 13; 38(1):254. PubMed ID: 31196210
    [Abstract] [Full Text] [Related]

  • 15. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y, Wu J, Yan H, Cheng Y, Wang Y, Yang Y, Deng M, Che X, Hou K, Qu X, Zou D, Liu Y, Zhang Y, Hu X.
    Pharmacol Res; 2020 Sep 13; 159():105007. PubMed ID: 32561477
    [Abstract] [Full Text] [Related]

  • 16. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
    Zheng Q, Dong H, Mo J, Zhang Y, Huang J, Ouyang S, Shi S, Zhu K, Qu X, Hu W, Liu P, Wang Y, Zhang X.
    Theranostics; 2021 Sep 13; 11(2):824-840. PubMed ID: 33391507
    [Abstract] [Full Text] [Related]

  • 17. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.
    Van Schaeybroeck S, Kyula J, Kelly DM, Karaiskou-McCaul A, Stokesberry SA, Van Cutsem E, Longley DB, Johnston PG.
    Mol Cancer Ther; 2006 May 13; 5(5):1154-65. PubMed ID: 16731747
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.
    Wang F, Meng F, Wong SCC, Cho WCS, Yang S, Chan LWC.
    Ther Adv Respir Dis; 2020 May 13; 14():1753466620915156. PubMed ID: 32552611
    [Abstract] [Full Text] [Related]

  • 19. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J, You L, Yao J, Xie J, Jing J, Jing Z, Jiang L, Sui X, Pan H, Han W.
    Cancer Lett; 2016 Aug 28; 379(1):124-33. PubMed ID: 27264264
    [Abstract] [Full Text] [Related]

  • 20. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M, Yuan Y, Pan YY, Zhang Y.
    Mol Med Rep; 2014 Jun 28; 9(6):2417-22. PubMed ID: 24682085
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.